Skip to main content

Biomedical Research in Urology

The Biomedical Research in Urology group is interested in the study of hormone-dependent cancers, in particular prostate cancer (but not limited to it).

Our efforts are focused on finding, on the one hand, tools that help us in the early diagnosis of the disease, in the best differentiation of tumors according to their aggressiveness and their response to therapy, and finally in finding effective therapies against it.

From a molecular point of view, we focus our studies mainly on cell signaling processes related to the cell cycle and mitosis (with kinesins, kinases and ubiquitin ligases as main targets).

Our multidisciplinary group is made up of molecular biologists and urologists, and we collaborate with oncologists, pathologists and specialists in other diseases when required.

We work with in silico data obtained with different "omics" techniques, samples and clinical data from patients, in vitro and in vivo models, to answer the questions raised.

Team

Joan Morote Robles

Joan Morote Robles

Head of group
Biomedical Research in Urology
Read more
Ana Celma Domènech

Ana Celma Domènech

Biomedical Research in Urology
Read more
Inés de Torres Ramirez

Inés de Torres Ramirez

Biomedical Research in Urology
Read more
Mercè Cuadras Solé

Mercè Cuadras Solé

Biomedical Research in Urology
Read more
Anna Santamaria Margalef

Anna Santamaria Margalef

Head of group
Biomedical Research in Urology
Read more
Carlos Serrano Burgos

Carlos Serrano Burgos

Read more
Joan Morote Robles

Joan Morote Robles

Head of group
Biomedical Research in Urology
Read more
Ana Celma Domènech

Ana Celma Domènech

Biomedical Research in Urology
Read more
Inés de Torres Ramirez

Inés de Torres Ramirez

Biomedical Research in Urology
Read more
Mercè Cuadras Solé

Mercè Cuadras Solé

Biomedical Research in Urology
Read more
Anna Santamaria Margalef

Anna Santamaria Margalef

Head of group
Biomedical Research in Urology
Read more
Carlos Serrano Burgos

Carlos Serrano Burgos

Read more

Research lines

Bone metastases in prostate cancer (Translational research in prostate cancer)

Once the tumor metastasizes to bone, the metastatic disease become incurable and current therapies are palliative. Thus, to better understand the biology of PC bone metastasis and to investigate new therapeutic options it is crucial to develop new animal models. We have established new experimental models of PC bone metastasis by inoculation (intratibial and intracardiac) of human PC cell lines in immunodeficient mice to make a suitable model for evaluating novel compounds as future therapeutic approaches. Extensive bone metastases were monitored by in vivo bioluminescence imaging. By applying different strategies we have described new molecular targets involved in the mechanisms of PC bone metastasis. 1) Garcia M, et al. BJU Int. 2014;113:E164-77. 2) Doll A, et al. Arch Esp Urol. 2013;66:463-74.

IP: Joan Morote Robles

Cell Cycle and Cancer.

Principal Investigator Anna Santamaría Margalef, PhD Clinical Associated Researchers Juan Morote Robles, MD, PhD (co-head Biomedical Research Group in Urology) Jacques Planas, MD, PhD   PhD Students Letícia Suárez Marta Barber Technician Adrián García Past members Dr. Núria Masiá Dr. Melissa Bradbury (MD) Dr. Alfonso Parrilla Dr. Mireia Oliván Dr. Blanca Majem Gabriel Tamayo BACKGROUND The efforts of our team are devoted to give answer to the main challenges in the field of cancer (diagnosis, prognosis and therapy), in particular we focus our attention to homone-dependent tumors, namely prostate tumors (but not limited to) and on cell cycle-related signaling pathways, specifically mitosis and the role of key regulatory enzymes (kinesins, kinases and ubiquitin ligases). RESEARCH STRATEGY AND SCOPE Alternative therapeutic strategies based on mitotic regulators: kinesins Alterations in the expression of several mitotic regulators have been associated with tumor formation in many cancers. Recent genomic studies have shown that androgen receptor (AR) activity in hormone-refractory prostate cancer (PCa) is not identical to that displayed in androgen dependent cells. Interestingly, increasing evidence in the last years suggest that castrated-resistance prostate cancer (CRPC) cells have undergone a genetic reprogramming to upregulate the expression of M-phase cell cycle genes. AR selectively and directly upregulates a set of mitotic regulators to promote androgen independent PCa. Enrichment of M-phase proteins and pathways has been found in CRPC chemotherapy-resistant tumors compared with their chemotherapy-naïve counterparts. In this context, the main goal of this research line is to gain novel molecular insights into the progression of PCa, with special emphasis on the involvement of mitotic regulators in the acquisition of prostate tumors androgen independence. Through a proteomic-based approach we have identified drivers of the castration-resistant disease and several mitotic kinesins stand out. We aim at studying their role as potential as therapeutic targets. Contribution to disfunctionality of mitotic regulators alterations to CIN in certain tumors We aim at understanding first, the basic molecular mechanisms by which mitotic players (spindle-associated proteins and mitotic kinases such us hBora, Ska, CHICA, Plk1, Aurora A) that normally operate to ensure the error-free segregation of chromosomes, and how are they regulated in time and space and second, and which mechanisms give rise to the chromosomal instability that is typical of tumor cells by taking advantage of the animal and human models of cancer currently used in the laboratory. BRCA1 and BRCA2-dependent ubiquitination and phosphorylation landscapes in cancer patients High-grade serous carcinoma (HGSC) is characterized by presenting defects in the homologous recombination repair, most frequently associated to BRCA1 mutations. Although most patients will initially respond to first-line chemotherapy with platinum-based agents, up to a quarter will be resistant to treatment. In recent years we have advanced in the understanding of HGSC tumour physiology and its dependence on BRCA1 and, secondly, have identified protein signature able to discriminate between chemotherapy resistant and sensitive patients. In collaboration with the clinicians at the Gynecology Department at the Vall Hebron Hospital, we have performed a multi-layered proteomic characterization of patient-derived ovarian tissues, which has revealed the importance of both ubiquitination and phosphorylation layers of regulation in modulating key cellular processes in HGSC, their dependency on BRCA1 and the identification of BRCA1 substrates responsible for driving ubiquitination signalling. Also, using discovery and targeted proteomics in HGSC tissues, we have identified a protein signature able to discriminate between chemotherapy resistant and sensitive patients at the time of cancer diagnosis. Collectively, we have performed a comprehensive molecular characterization of HGSC that provides a groundwork for future mechanistic-based studies and the development of new targeted therapies in ovarian cancer. In addition, we advance in the optimization of therapeutic decision making through the identification of a promising protein signature able to predict response to chemotherapy. On the other hand, previous sequencing studies revealed that alterations of genes associated with DNA damage response (DDR) are enriched in men with mCRPC. Although BRCA2 mutations are known to confer an increased risk of breast and ovarian cancer, recent observations have shown that alterations of BRCA2 are more prevalent than previously appreciated in men with PCa and more frequent than alterations in any other DDR gene. We aim at translating our expertise and results on BRCA1 related to HGSC, to get deeper insights into the functional relevance of BRCA2 mutations in PCa. In close collaboration with the Urology Deparment at Vall Hebron (Dr. Jacques Planas), we also aim at improving the management of patients with BRCA2 mutations. Drug development We are interested in testing the therapeutic potential of new synthetic or natural compounds in clinically representative tumor cell lines (of prostate and ovarian cancer) and preclinical mouse models to improve the efficacy and safety of currently available treatments.  ONGOING and PAST COMPETITIVE PROJECTS: 1. 2019PROD00087, SalivOmiX: Prova basada en la detecció de miRNAs en saliva per el diagnòstic precoç del càncer d'ovari  AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Producte.  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/07/2020-31/12/2021. 100.000 €. 2. PI18/01017,  SalivOmiX: Test basado en el análisis de miRNAs en saliva para la detección precoz del cáncer de ovario   Instituto de Salud Carlos III (FIS). (INSTITUTO DE INVESTIGACION HOSPITAL UNIVERSITARIO VALLE DE HEBRON).  01/2019- 12/2021. 159.720 €. Investigador principal. 3. 2017 SGR 1661,  Grup de Recerca Biomèdica en Ginecologia  AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. SGR.  Anronio Gil Moreno.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON).  01/01/2018- 31/12/2020. 33.000 €. Miembro de equipo. 4. AECC/2017/SANTAMARIA,  Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la kinesina KIF11   Asociación Española Contra el Cáncer. AECC - Junta Barcelona (Conveni ajudes per a la investigació 2017).  Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2018-2019. 34.700 €. Investigador principal. 5. 2016 LLAV 00056, Salivomics: identification of genòmic markers to improve early ovarian càncer detection   AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Llavor. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2017-2018. 20.000 €. Investigador principal. 6. PI15/02238, Sensibilidad a quimioterapia en cáncer de ovario: Plk1 y Aurora A quinasas como terapia alternativa que permitan mejorar la respuesta antitumoral y la estratificación de pacientes  FIS. Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2016-2018. 122.815 €. Investigador principal. 7. RTC-2015-3821-1,  Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cáncer ginecológico (PredicareGYN)   Ministerio de Economía y Competitividad. RETOS.  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2015-2018. 348,6 €. Co-Investigador principal. 8. Transcripció, traducció i mitosi en càncer de pròstata resistent a teràpia.TRAMIT-CAP (GRE)   AGENCIA DE GESTIO D'AJUTS UNIVERSITARIS I DE RECERCA. Grup de Recerca Emergent (SGR-AGAUR). Anna Santamaria Margalef. (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 01/01/2014-31/12/2016. 16.000 €. Co-Investigador principal. 9. CP13/00158,  Characterization of Plk1 alterations and consequences in the progression tumorigenesis, with a focus in prostate cancer   Miguel Servet (FIS).  Anna Santamaria Margalef.  (FUNDACIO INSTITUT DE RECERCA DE L'HOSPITAL UNIV. VALL D'HEBRON). 2014-2016. 120.500 €. Investigador principal. 10. Control of chromosome segregation fidelity   Swiss Cancer League. Anna Santamaria Margalef.  (Biozentrum - University of Basel).  02/2011-02/2014.  160.000  €.  Investigador principal. ACTIVE COLLABORATIONS WITH BIOTECH COMPANIES: Atrys (Madrid, Spain) Oncostellae (Santiago de Compostela, Spain) 4SC (Münich, Germany) SELECTED PUBLICATIONS (last 5 years) Currently under review: - Bradbury M; … Gil-Moreno A; Sabidó E*; Santamaria, A*. BRCA1 mutations reshape the signaling landscape in high-grade serous ovarian cancer patients. Science Signalling (under review) (*equal contribution). - Bradbury M; … Gil-Moreno A; Santamaria, A*; Sabidó E*. Molecular advances for the management of high-grade serous ovarian cancer patients. Cancers (under review) (*equal contribution). 1.- Alfonso Parrilla; Marta Barber; Blanca Majem; et al.,; Miguel F Segura; Antonio Gil Moreno; Anna Santamaria. Aurora Borealis (Bora), Which Promotes Plk1 Activation by Aurora A, Has an Oncogenic Role in Ovarian Cancer. Cancers (Basel). 12 - 4, pp. pii:E886. 06/04/2020. DOI: 10.3390/cancers12040886. 2.- Blanca Majem; Alfonso Parrilla; et al.,; Antonio Gil Moreno; Miguel F Segura; Anna Santamaría. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 38 - 32, pp. 6035 - 6050. 08/2019. ISSN 1476-5594 DOI: 10.1038/s41388-019-0860-0 3.- Soriano A; Masanas M; Boloix A; et al; Santamaria A; Segura MF. 2019. Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as a new tumour-suppressive microRNAs in neuroblastoma. Cell Mol Life Sci. 76-11, pp.2231-2243. ISSN 2041-1723. 4.- Óscar Rapado-González, Blanca Majem, et al., Anna Santamaría, Rafael López-López, Laura Muinelo-Romay, María Mercedes Suarez-Cunqueiro. A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis. J. Clin. Med. 2019, 8, 2029;doi:10.3390/jcm8122029 5.- Óscar Rapado-González, Blanca Majem, Laura Muinelo-Romay, Ana Álvarez-Castro, Anna Santamaría , Antonio Gil-Moreno , Rafael López-López , María Mercedes Suárez-Cunqueiro. Human salivary microRNAs in Cancer. J Cancer.  2018 Jan 6;9(4):638-649. doi: 10.7150/jca.21180. eCollection 2018. 6.-Devis, L; Moiola, C; Masia, N; et al; Santamaria, A; Colas, E. 2017. Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion and metastasis in early stage endometrioid endometrial cáncer. Journal of Pathology. WILEY-BLACKWELL. 241-4, pp.475-487. ISSN 0022-3417. 7.- A Almazán-Moga, P Zarzosa, C Molist, P Velasco , J Pyczek, K Simon-Keller, I Giralt, I Vidal, N Navarro, M F Segura, A Soriano, S Navarro, O M Tirado, J C Ferreres, A Santamaria, R Rota, H Hahn, J Sánchez de Toledo , J Roma, S Gallego. 2017. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. Br J Cancer. 117-9, pp.1314-1325. ISSN 0007-0920. 1 8.- Redli, PM; Gasic, I; Meraldi, P; Nigg, EA; Santamaria, A. The Ska complex promotes Aurora B activity to ensure chromosome biorientation. Journal of Cell Biology. 215 - 1, pp. 77 – 93, 2016. ROCKEFELLER UNIV PRESS, 10/10/2016. ISSN 0021-9525DOI: 10.1083/jcb.201603019 9.- Thomas, Y.; Cirillo, L.; Panbianco, C.; et al; Santamaria, A.; Gotta, M. 2016. Cdk1 Phosphorylates SPAT-1/Bora to Promote Plk1 Activation in C. elegans and Human Cells. Cell Reports. CELL PRESS. 15-3, pp.510-518. ISSN 2211-1247. 10.- Abad, MA; Zou, J; Medina-Pritchard, B; Nigg, EA; Rappsilber, J; Santamaria, A; Jeyaprakash, AA. 2016. Ska3 Ensures Timely Mitotic Progressionby Interacting Directly With Microtubules and Ska1 Microtubule Binding Domain. Scientific Reports. NATURE PUBLISHING GROUP. 6, pp.34042. ISSN 2045-2322. 11.- Maria-Alba* Abad; Medina, B*; Santamaria, A*; Zou, J; Plasberg-Hill, C; Madhumalar, A; Jayachandran, U; Rappsilber, J; Nigg, EA; Jeyaprakash, AA. Structural Basis for the Microtubule-Recognition by the human kinetochore Ska complex. Nature Communications. 5, pp. 2964. NATURE PUBLISHING GROUP, 2015. ISSN 2041-1723 (*equal contribution)

IP: Anna Santamaria Margalef

Cell signaling and cancer progression

Prostate cancer (PC) is the second leading cause of death for cancer in men of the western Countries. While considerable advances have been made in the treatment of localized, organ-confined tumors, metastatic PC is virtually incurable and most deaths from this disease are due to the high resistance of metastasis to conventional therapies (androgen-depletion-therapy, ADT). Therefore, more precise markers for the detection of the incipient resistant tumor and more effective targets that eliminate the resistant clones are needed. A principal aim is to identify relevant molecular pathways specifically active in aggressive prostate cancer, useful for an early detection of ADT resistant tumors and for treatment strategies. In our studies, we have discovered the human Prostate Tumor OVerexpressed-1 (PTOV1) gene, later called Acid-2, and a second gene with a PTOV module, PTOV2, later called MED25, a component of Mediator (1-2). The detection of PTOV1 in high-grade PIN (HGPIN) premalignant lesions is helpful to identify patients with higher probability to develop PC (3). PTOV1 ectopic expression promotes proliferation, invasion and metastasis of ADT resistant cells (1,2,4,5). PTOV1 induces the epithelial-mesenchymal-transition (EMT) and increased metastasis of PC3 cells (4). Mechanistically, PTOV1 is implicated in multiple processes controlling cell fate: it promotes mRNA translation leading to a specific increased synthesis of c-Jun and Snai1 oncogenes (4), and it is a transcriptional repressor of HES1 and HEY1 genes, leading to inhibition of Notch signalling in metastatic PC (5). PTOV1 significantly affect the self-renewal potential of the cancer stem cell populations of PC3 cells (5). Current objectives of our line of research are: (i) Determine the role of PTOV1 in the resistance to ADT and chemotherapy (taxols). (ii) Characterize the sub-clonal cancer stem cell populations (CSC) present in metastatic primary tumors and the genes and factors responsible for the development of the resistance to ADT. 1) Benedit P, et al. Oncogene 2001;20:1455–1464. 2) Santamaria A, et al. Am J Pathol 2003;162:897–905. 3) Morote J, et al. Clin Cancer Res 2008:14:2617-2622. 4) Marqués N, et al. Oncogene 2014;33(9):1124-34. 5) Alaña L et al., Mol Cancer 2014;13:74.

IP: Rosanna Paciucci Barzanti

Development of non-invasive methods for the early detection of prostate cancer (Translational research in prostate cancer)

One main focus of our research is the discovery of new biomarkers for the early detection of prostate cancer (PC). The detection of proteins, RNA or miRNAs from easily accessible body fluids, such as blood or urine, will make possible to diagnose the disease at an early/pre-symptomatic stage, or monitoring responses to therapy in a simple and non-invasive way. This will improve the specificity of the currently used PSA serum measurements. We have identified a three-gene panel in urine able to increase the PSA specificity for the detection of PC, and using liquid chromatography, mass spectrometry and triple quadruple mass spectrometry (LC/MSMS, SRM), we have discovered the presence of specific, differential proteomic profiles in the urine of PC patients. Furthermore, we have identified a genomic profile able to detect PC in patients previously diagnosed with high-grade prostatic intraepithelial neoplasia (HGPIN). Such profile should have an application in the clinics and improve decision making in the diagnosis and treatment of PC (Figure). 1) Sequeiros T, et al. Prostate 2015; Accepted; 2) Rigau M*, Olivan M*, et al. Int. J. Mol. Sci. 2013;14: 12620-12649; 3) Rigau M, et al. Prostate 2011; 71:1736-45; 4) Rigau M et al. Prostate 2010; 70:1760-7

IP: Joan Morote Robles

Projects

Pendent

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII18/00027
Duration: 01/02/2019 - 31/01/2022

Noves estratègies terapèutiques pel tractament del càncer de pròstata hormonorefrectari

IP: Joan Morote Robles
Collaborators: Marta Barber Servera, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 52963.21
Reference: 2020FI_B 00058
Duration: 01/09/2020 - 31/08/2023

Nuevos enfoques terapéuticos para el cáncer de próstata hormono-refractario basados en la kinesina KIF11

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez
Funding agency: Instituto de Salud Carlos III
Funding: 105270
Reference: PI17/02248
Duration: 01/01/2018 - 30/06/2022

SalivOmiX: Test basado en el análisis de miRNAS en saliva para la detección precoz de cáncer de ovario.

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Maria Asuncion Perez Benavente, José Luis Sánchez Iglesias, Melissa Bradbury Lobato
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI18/01017
Duration: 01/01/2019 - 30/06/2023

Patient (ascites)-Derived Xenograft Models to evaluate

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: VHIR/PREDOC/2017/LETICIA SUAREZ
Duration: 01/03/2018 - 28/02/2021

Pendent

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII18/00027
Duration: 01/02/2019 - 31/01/2022

FPII per Grup d'Investigació en Urología

IP: Joan Morote Robles
Collaborators: Adrian Garcia Rodriguez, Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 35800
Reference: PEJ2018-002742-A
Duration: 01/09/2019 - 31/08/2021

Noves estratègies terapèutiques pel tractament del càncer de pròstata hormonorefrectari

IP: Joan Morote Robles
Collaborators: Marta Barber Servera, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 52963.21
Reference: 2020FI_B 00058
Duration: 01/09/2020 - 31/08/2023

Patient (ascites)-Derived Xenograft Models to evaluate

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: VHIR/PREDOC/2017/LETICIA SUAREZ
Duration: 01/03/2018 - 28/02/2021

Pendent

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII18/00027
Duration: 01/02/2019 - 31/01/2022

FPII per Grup d'Investigació en Urología

IP: Joan Morote Robles
Collaborators: Adrian Garcia Rodriguez, Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 35800
Reference: PEJ2018-002742-A
Duration: 01/09/2019 - 31/08/2021

Noves estratègies terapèutiques pel tractament del càncer de pròstata hormonorefrectari

IP: Joan Morote Robles
Collaborators: Marta Barber Servera, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 52963.21
Reference: 2020FI_B 00058
Duration: 01/09/2020 - 31/08/2023

Sol·licitud Melissa.

IP: Anna Santamaria Margalef
Collaborators: Melissa Bradbury Lobato, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 107196
Reference: PHD4MD/04/BRADBURY/2016
Duration: 01/10/2016 - 30/09/2019

Noves teràpies dirigides al tractament del càncer de pròstata en estadis avançats Nuevas Terápias dirigidas al tractament del Càncer de próstata en estadios avanzados.

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 97725.21
Reference: SLT002/16/00362
Duration: 03/06/2017 - 14/09/2019

Patient (ascites)-Derived Xenograft Models to evaluate

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: VHIR/PREDOC/2017/LETICIA SUAREZ
Duration: 01/03/2018 - 28/02/2021

Pendent

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 101250
Reference: CPII18/00027
Duration: 01/02/2019 - 31/01/2022

Paper de les quinases mitòtiques en la transformació maligna prostàtica

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-11
Duration: 09/02/2015 - 08/02/2018

Sol·licitud Melissa.

IP: Anna Santamaria Margalef
Collaborators: Melissa Bradbury Lobato, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 107196
Reference: PHD4MD/04/BRADBURY/2016
Duration: 01/10/2016 - 30/09/2019

Noves teràpies dirigides al tractament del càncer de pròstata en estadis avançats Nuevas Terápias dirigidas al tractament del Càncer de próstata en estadios avanzados.

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 97725.21
Reference: SLT002/16/00362
Duration: 03/06/2017 - 14/09/2019

Patient (ascites)-Derived Xenograft Models to evaluate

IP: Anna Santamaria Margalef
Collaborators: Leticia Suarez Cabrera, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: VHIR/PREDOC/2017/LETICIA SUAREZ
Duration: 01/03/2018 - 28/02/2021

Paper de les quinases mitòtiques en la transformació maligna prostàtica

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-11
Duration: 09/02/2015 - 08/02/2018

Sol·licitud Melissa.

IP: Anna Santamaria Margalef
Collaborators: Melissa Bradbury Lobato, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 107196
Reference: PHD4MD/04/BRADBURY/2016
Duration: 01/10/2016 - 30/09/2019

Noves teràpies dirigides al tractament del càncer de pròstata en estadis avançats Nuevas Terápias dirigidas al tractament del Càncer de próstata en estadios avanzados.

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 97725.21
Reference: SLT002/16/00362
Duration: 03/06/2017 - 14/09/2019

Perfiles de MicroRNA como biomarcadores predictivos del cáncer de próstata agresivo para la optimización de las decisiones terapéuticas

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez, Alex Sánchez Pla, Jacques Planas Morin
Funding agency: Instituto de Salud Carlos III
Funding: 57475
Reference: PI13/00173
Duration: 01/01/2014 - 30/06/2018

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012
Duration: 05/11/2012 - 31/12/2016

Paper de les quinases mitòtiques en la transformació maligna prostàtica

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-11
Duration: 09/02/2015 - 08/02/2018

Sol·licitud Melissa.

IP: Anna Santamaria Margalef
Collaborators: Melissa Bradbury Lobato, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 107196
Reference: PHD4MD/04/BRADBURY/2016
Duration: 01/10/2016 - 30/09/2019

Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama

IP: -
Collaborators: Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama, Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama
Funding agency: Instituto de Salud Carlos III
Funding: 74415
Reference: PI12/02727
Duration: 01/01/2013 - 22/04/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012
Duration: 05/11/2012 - 31/12/2016

Paper de les quinases mitòtiques en la transformació maligna prostàtica

IP: Anna Santamaria Margalef
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 46800
Reference: PRED-VHIR-2014-11
Duration: 09/02/2015 - 08/02/2018

Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama

IP: -
Collaborators: Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama, Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama
Funding agency: Instituto de Salud Carlos III
Funding: 74415
Reference: PI12/02727
Duration: 01/01/2013 - 22/04/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012 DUPLICAT 2014.7 ACCIONS ESPECIALS
Duration: 05/11/2014 - 31/12/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012
Duration: 05/11/2012 - 31/12/2016

Perfiles proteómicos de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del cáncer de próstata

IP: Joan Morote Robles
Collaborators: José Placer Santos, Jacques Planas Morin
Funding agency: Instituto de Salud Carlos III
Funding: 108900
Reference: PI11/02486
Duration: 01/01/2012 - 31/12/2014

Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama

IP: -
Collaborators: Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama, Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama
Funding agency: Instituto de Salud Carlos III
Funding: 74415
Reference: PI12/02727
Duration: 01/01/2013 - 22/04/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012 DUPLICAT 2014.7 ACCIONS ESPECIALS
Duration: 05/11/2014 - 31/12/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012
Duration: 05/11/2012 - 31/12/2016

Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del càncer de próstata

IP: Joan Morote Robles
Collaborators: Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del , Inés de Torres Ramirez, Marina Rigau Resina
Funding agency: Fundación Investigación Urologia
Funding: 36000
Reference: FIU-2011-01
Duration: 23/08/2011 - 30/06/2013

Perfiles proteómicos de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del cáncer de próstata

IP: Joan Morote Robles
Collaborators: José Placer Santos, Jacques Planas Morin
Funding agency: Instituto de Salud Carlos III
Funding: 108900
Reference: PI11/02486
Duration: 01/01/2012 - 31/12/2014

Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama

IP: -
Collaborators: Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama, Prevención de las recaídas mediante ejercicio, dieta y control de peso en pacientes con cáncer de mama
Funding agency: Instituto de Salud Carlos III
Funding: 74415
Reference: PI12/02727
Duration: 01/01/2013 - 22/04/2016

Global Prostate Cancer Biomarker Initiative

IP: -
Collaborators: -
Funding agency: The Movember Group Pty Ltd
Funding: 31200
Reference: GPCBI_MVM2012
Duration: 05/11/2012 - 31/12/2016

Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del càncer de próstata

IP: Joan Morote Robles
Collaborators: Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del , Inés de Torres Ramirez, Marina Rigau Resina
Funding agency: Fundación Investigación Urologia
Funding: 36000
Reference: FIU-2011-01
Duration: 23/08/2011 - 30/06/2013

Perfiles proteómicos de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del cáncer de próstata

IP: Joan Morote Robles
Collaborators: José Placer Santos, Jacques Planas Morin
Funding agency: Instituto de Salud Carlos III
Funding: 108900
Reference: PI11/02486
Duration: 01/01/2012 - 31/12/2014

Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del càncer de próstata

IP: Joan Morote Robles
Collaborators: Validación de un perfil proteómico de biomarcadores en orina post-masaje prostático como predictor del riesgo y agresividad del , Inés de Torres Ramirez, Marina Rigau Resina
Funding agency: Fundación Investigación Urologia
Funding: 36000
Reference: FIU-2011-01
Duration: 23/08/2011 - 30/06/2013

Análisis del perfil transcripcional genómico en la Atrofia Proliferativa Inflamatoria (PIA) como lesión precursora del cáncer de próstata humano

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez, Ma Teresa Quiles Pérez, Maria Antonia Arbos Via
Funding agency: Instituto de Salud Carlos III
Funding: 124630
Reference: PI070536
Duration: 01/01/2008 - 30/12/2010

Identificación de marcadores proteómicos en orina para la detección precoz del cáncer de próstata Convocatoria "Pedro Cifuentes Díaz" 2007

IP: Joan Morote Robles
Collaborators: -
Funding agency: Fundación Investigación Urologia
Funding: 36300
Reference: FIU_01_2007
Duration: 01/02/2008 - 31/01/2010

Análisis del perfil transcripcional genómico en la Atrofia Proliferativa Inflamatoria (PIA) como lesión precursora del cáncer de próstata humano

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez, Ma Teresa Quiles Pérez, Maria Antonia Arbos Via
Funding agency: Instituto de Salud Carlos III
Funding: 124630
Reference: PI070536
Duration: 01/01/2008 - 30/12/2010

Identificación de marcadores proteómicos en orina para la detección precoz del cáncer de próstata Convocatoria "Pedro Cifuentes Díaz" 2007

IP: Joan Morote Robles
Collaborators: -
Funding agency: Fundación Investigación Urologia
Funding: 36300
Reference: FIU_01_2007
Duration: 01/02/2008 - 31/01/2010

Mecanismos moleculares de la participación del eje fibroblasto-célula inflamatoria en la iniciación y progresión del cáncer de próstata

IP: Joan Morote Robles
Collaborators: Ma Teresa Quiles Pérez
Funding agency: Fundación Investigación Urologia
Funding: 36400
Reference: UROL/2/2006
Duration: 01/05/2006 - 30/04/2008

Análisis del perfil transcripcional genómico en la Atrofia Proliferativa Inflamatoria (PIA) como lesión precursora del cáncer de próstata humano

IP: Joan Morote Robles
Collaborators: Inés de Torres Ramirez, Ma Teresa Quiles Pérez, Maria Antonia Arbos Via
Funding agency: Instituto de Salud Carlos III
Funding: 124630
Reference: PI070536
Duration: 01/01/2008 - 30/12/2010

Identificación de marcadores proteómicos en orina para la detección precoz del cáncer de próstata Convocatoria "Pedro Cifuentes Díaz" 2007

IP: Joan Morote Robles
Collaborators: -
Funding agency: Fundación Investigación Urologia
Funding: 36300
Reference: FIU_01_2007
Duration: 01/02/2008 - 31/01/2010

Mecanismos moleculares de la participación del eje fibroblasto-célula inflamatoria en la iniciación y progresión del cáncer de próstata

IP: Joan Morote Robles
Collaborators: Ma Teresa Quiles Pérez
Funding agency: Fundación Investigación Urologia
Funding: 36400
Reference: UROL/2/2006
Duration: 01/05/2006 - 30/04/2008

Mecanismos moleculares de la participación del eje fibroblasto-célula inflamatoria en la iniciación y progresión del cáncer de próstata

IP: Joan Morote Robles
Collaborators: Ma Teresa Quiles Pérez
Funding agency: Fundación Investigación Urologia
Funding: 36400
Reference: UROL/2/2006
Duration: 01/05/2006 - 30/04/2008

Expresión de factores angiogénicos VEGF, bFGF y sus receptores flt-1 y flK/KDR en las lesiones de PIN (Neoplasia Intraepitelial Prostática) y su relación con el desarrollo del carcinoma invasivo prostático humano.

IP: Inés de Torres Ramirez
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 13823.28
Reference: 00/0915
Duration: 01/11/2000 - 01/11/2001

Expresión de factores angiogénicos VEGF, bFGF y sus receptores flt-1 y flK/KDR en las lesiones de PIN (Neoplasia Intraepitelial Prostática) y su relación con el desarrollo del carcinoma invasivo prostático humano.

IP: Inés de Torres Ramirez
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 13823.28
Reference: 00/0915
Duration: 01/11/2000 - 01/11/2001

Publications

Behavior of SelectMDx and Prostate-specific Antigen Density in the Challenging Scenario of Prostate Imaging-Reporting and Data System Category 3 Lesions.

PMID: 34602313
Journal: EUROPEAN UROLOGY
Year: 2022
Reference: Eur Urol. 2022 Jan;81(1):124-125. doi: 10.1016/j.eururo.2021.09.019. Epub 2021 Sep 30.
Impact factor: 20.096
Publication type: Letter whit IF
Authors: Morote, Juan; Diaz, Fernando; Celma, Anna; Planas, Jacques; Trilla, Enrique et al.
DOI: 10.1016/j.eururo.2021.09.019

Multidisciplinary Consensus on the Prevention and Treatment of Osteoporosis and Fragility Fractures in Patients with Prostate Cancer Receiving Androgen-Deprivation Therapy.

PMID: 34983087
Journal: World Journal of Mens Health
Year: 2022
Reference: World J Mens Health. 2022 Jan;40(1):74-86. doi: 10.5534/wjmh.210061.
Impact factor: 5.4
Publication type: Review in international publication
Authors: Casado, Enrique; Borque-Fernando, Angel; Caamano, Manuel; Grana, Jenaro; Munoz-Rodriguez, Jesus; Morote, Juan et al.
DOI: 10.5534/wjmh.210061

Is Tumor Budding a New Predictor for Early Cystectomy in pT1 High-Grade Bladder Cancer?

PMID: 34352790
Journal: UROLOGIA INTERNATIONALIS
Year: 2022
Reference: Urol Int. 2022;106(2):154-162. doi: 10.1159/000517543. Epub 2021 Aug 5.
Impact factor: 2.089
Publication type: Paper in international publication
Authors: Raventos Busquets, Carles X; Semidey, M Eugenia; Lozano Palacio, Fernando; Carrion Puig, Albert; Aula Olivar, Ana; De Torres Ramirez, Ines M; Trilla Herrera, Enrique et al.
DOI: 10.1159/000517543

Experience and results after the implementation of a radiology day unit in a reference hospital.

PMID: 35767122
Journal: Insights into Imaging
Year: 2022
Reference: Insights Imaging. 2022 Jun 29;13(1):109. doi: 10.1186/s13244-022-01251-2.
Impact factor: 5.231
Publication type: Paper in international publication
Authors: Escobar, Manuel; Tomasello, Alejandro; Perez Lafuente, Mercedes; Andreu, Jordi; Grinon, Jesus; Sanchez-Tirado, Cristina; Mast, Richard; Antolin, Andreu; Roson, Nuria et al.
DOI: 10.1186/s13244-022-01251-2

Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples.

PMID: 34944822
Journal: Cancers
Year: 2021
Reference: Cancers (Basel). 2021 Dec 9;13(24). pii: cancers13246202. doi: 10.3390/cancers13246202.
Impact factor: 6.639
Publication type: Paper in international publication
Authors: Santamaria, Anna, Rodriguez-Barrueco, Ruth, Morote, Juan, de la Cruz, Xavier, Olivan, Mireia, Garcia, Marta, Suarez, Leticia, Guiu, Marc, Gros, Laura, Mendez, Olga et al.
DOI: 10.3390/cancers13246202

The position of urethrovesical anastomosis after robotic radical prostatectomy assessed by MRI predicts early functional recovery: A cohort analyses from a randomized clinical trial.

PMID: 33607371
Journal: EUROPEAN JOURNAL OF RADIOLOGY
Year: 2021
Reference: Eur J Radiol. 2021 Apr;137:109589. doi: 10.1016/j.ejrad.2021.109589. Epub 2021 Feb 12.
Impact factor: 3.528
Publication type: Paper in international publication
Authors: Salazar, Aina, Planas, Jacques, Celma, Ana, Cuadras, Merce, Roche, Sarai, Mast, Richard, Morote, Juan, Trilla, Enrique, Regis, Lucas et al.
DOI: 10.1016/j.ejrad.2021.109589

Autophagy Takes Center Stage as a Possible Cancer Hallmark.

PMID: 33194736
Journal: Frontiers in Oncology
Year: 2020
Reference: Front Oncol. 2020 Oct 22;10:586069. doi: 10.3389/fonc.2020.586069. eCollection 2020.
Impact factor: 4.848
Publication type: Review in international publication
Authors: Kondoh, Hiroshi, Alvarez-Meythaler, Jose G, Garcia-Mayea, Yoelsis, Mir, Cristina, LLeonart, Matilde E et al.
DOI: 10.3389/fonc.2020.586069

STK11 (LKB1) missense somatic mutant isoforms promote tumor growth, motility and inflammation.

PMID: 32647375
Journal: Communications Biology
Year: 2020
Reference: Commun Biol. 2020 Jul 9;3(1):366. doi: 10.1038/s42003-020-1092-0.
Impact factor: 4.165
Publication type: Paper in international publication
Authors: Granado-Martinez, Paula, Garcia-Ortega, Sara, Gonzalez-Sanchez, Elena, McGrail, Kimberley, Selgas, Rafael, Grueso, Judit, Gil, Rosa, Naldaiz-Gastesi, Neia, Rhodes, Ana C, Hernandez-Losa, Javier et al.
DOI: 10.1038/s42003-020-1092-0

A Novel Saliva-Based miRNA Signature for Colorectal Cancer Diagnosis.

PMID: 31757017
Journal: Journal of Clinical Medicine
Year: 2019
Reference: J Clin Med. 2019 Nov 20;8(12). pii: jcm8122029. doi: 10.3390/jcm8122029.
Impact factor: 5.688
Publication type: Paper in international publication
Authors: Rapado-Gonzalez, Oscar, Majem, Blanca, Alvarez-Castro, Ana, Diaz-Pena, Roberto, Abalo, Alicia, Suarez-Cabrera, Leticia, Gil-Moreno, Antonio, Santamaria, Anna, Lopez-Lopez, Rafael, Suarez-Cunqueiro, Maria Mercedes et al.
DOI: 10.3390/jcm8122029

MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

PMID: 31278368
Journal: ONCOGENE
Year: 2019
Reference: Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
Impact factor: 6.634
Publication type: Paper in international publication
Authors: Majem, Blanca, Parrilla, Alfonso, Jimenez, Carlos, Suarez-Cabrera, Leticia, Barber, Marta, Marin, Andrea, Castellvi, Josep, Tamayo, Gabriel, Moreno-Bueno, Gema, Ponce, Jordi et al.
DOI: 10.1038/s41388-019-0860-0

Thesis

Ús d'una matriu de col·lagen i elastina en la reparació d'un defecte vesical amb peritoneu parietal en model porcí

PhD student: Carlos Gasanz Serrano
Director/s: Joan Morote Robles, Carles Xavier Raventós Busquets
University: Universitat Autònoma de Barcelona
Year: 2018

The role of the oncogene Prostate Tumor Overexpressed-1 and the regulation of mRNA translation in Prostate Cancer progression and chemoresistance

PhD student: Verónica Cánovas Hernández
Director/s: Rosanna Paciucci Barzanti
University: Universitat Autònoma de Barcelona
Year: 2017

Valoracion del daño renal producido por el neumoperitoneo en un modelo experimental

PhD student: Ana Celma Domènech
Director/s: Jaume Reventós Puigjaner, Joan Morote Robles
University: Universitat Autònoma de Barcelona
Year: 2009

Blog

News

Novembre és el mes de la conscienciació sobre la salut masculina impulsada pel moviment MOVEMBER.

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

The drug EB1 is able to block resistance pathways to standard cancer treatments and could increase the efficacy of chemotherapy or immunotherapy.

Job offers

Postdoctoral Researcher BIOMEDICAL RESEARCH IN UROLOGY (Oncology)
Start date:
26/05/2022
End date:
09/06/2022
Document: Download
Cell Cycle and Cancer (Biomedical Research in Urology)
Start date:
20/05/2022
End date:
19/10/2022
Document: Download
Laboratory technician
Start date:
29/07/2021
End date:
12/08/2021
Document: Download